about
Erythropoietin in the general population: reference ranges and clinical, biochemical and genetic correlatesPRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotectionHigh-dose erythropoietin in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized controlled trials.Erythropoietin employs cell longevity pathways of SIRT1 to foster endothelial vascular integrity during oxidant stress.Translating cell survival and cell longevity into treatment strategies with SIRT1SIRT1: new avenues of discovery for disorders of oxidative stressEffect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial.Protection against ischemia/reperfusion‑induced renal injury by co‑treatment with erythropoietin and sodium selenite.The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment.Cardiac antiapoptotic and proproliferative effect of recombinant human erythropoietin in a moderate stage of chronic renal failure in the rat.Histopathological study of erythropoietin protective effect on carbon monoxide-induced cardiotoxicity in rat.Serum erythropoietin: a useful biomarker for coronary collateral development and potential target for therapeutic angiogenesis among the patients with coronary chronic total occlusion.Erythropoietin enhances migration of human neuroblastoma cells: in vitro studies and potential therapeutic implications.Impact of an interleukin-1 receptor antagonist and erythropoietin on experimental myocardial ischemia/reperfusion injury
P2860
Q28546759-99C2297F-BBEF-4A58-A00B-A6E0D65A8693Q34429082-79F8B864-1BAC-4DD7-8FD6-2202E177139FQ35008662-781AEC12-AD73-43A3-A8A6-56856FE58020Q35146283-9EF9AE04-F986-4513-B00F-C17BFD7327B2Q35660308-A182252C-F9DE-4442-995A-8A08ECEFA43EQ35757288-1CA38A85-5A6C-457C-8B84-C4E13569B294Q36256384-9F542E84-9CAD-444E-8EBB-FB7C52051C8EQ36592615-B577174C-D90B-4D4F-BEC7-DE4BBD7773DEQ37583865-03579E56-6180-4D3D-BF43-B41496CDCF72Q41398632-ACEA75C2-096C-496F-AD4F-101015FE339EQ47142543-32B51F6A-883B-40F5-8C8D-9B9983DD2FBCQ50995309-3E92B949-4F55-431E-AEFD-71C8C703F3B0Q54974179-560CC957-1063-4D84-903B-F83D06FF9F6BQ58915021-D2D401A1-4F2D-41DC-8149-41C7832394DA
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Erythropoietin and the heart: facts and perspectives.
@en
Erythropoietin and the heart: facts and perspectives.
@nl
type
label
Erythropoietin and the heart: facts and perspectives.
@en
Erythropoietin and the heart: facts and perspectives.
@nl
prefLabel
Erythropoietin and the heart: facts and perspectives.
@en
Erythropoietin and the heart: facts and perspectives.
@nl
P2860
P50
P356
P1433
P1476
Erythropoietin and the heart: facts and perspectives
@en
P2093
Elena Conti
P2860
P356
10.1042/CS20100305
P407
P577
2011-01-01T00:00:00Z